Comparative Pharmacology
Head-to-head clinical analysis: STAXYN versus VARDENAFIL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STAXYN versus VARDENAFIL HYDROCHLORIDE.
STAXYN vs VARDENAFIL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). By inhibiting PDE5, sildenafil increases intracellular cGMP levels in the corpus cavernosum, enhancing the relaxant effect of nitric oxide (NO) on smooth muscle cells, thereby facilitating penile erection in response to sexual stimulation.
Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). It enhances the effect of nitric oxide (NO) by inhibiting PDE5, which is responsible for degradation of cGMP in the corpus cavernosum. This results in increased cGMP levels, leading to smooth muscle relaxation and increased blood flow to the corpus cavernosum, thereby facilitating penile erection.
10 mg sublingually as needed, 30–60 minutes before sexual activity. Maximum 1 dose per 24 hours.
10 mg orally once daily as needed, approximately 60 minutes before sexual activity; maximum dose 20 mg; maximum frequency once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 4-5 hours; clinically, no accumulation with once-daily dosing
Terminal elimination half-life is approximately 4-5 hours in healthy subjects. In elderly patients (≥65 years) or those with hepatic impairment (Child-Pugh A/B), half-life may be prolonged up to 6-8 hours.
Renal (approximately 90% as metabolites, <2% unchanged); fecal (10%)
Primarily hepatic metabolism (CYP3A4, minor CYP2C9) followed by fecal excretion (approximately 91-95% of dose as metabolites) and renal excretion (approximately 2-6% as unchanged drug).
Category C
Category A/B
PDE5 Inhibitor
PDE5 Inhibitor